On 10/9/2020, the bwi product analysis lab received the complaint device for evaluation.The product analysis has begun but is not completed at this time.When the investigational analysis has been completed, a supplemental 3500a report will be submitted.If additional information is received regarding this event, a supplemental 3500a report will be submitted to the fda.Manufacturer's ref.# (b)(4).
|
It was reported that a female patient underwent cardiac ablation procedure for atrial fibrillation (afib) with pentaray nav high-density mapping eco catheter and suffered cardiac tamponade requiring surgical intervention.It was reported that the first transseptal puncture (brk needle with sl1 (abbott)) was done and the pentaray catheter was inserted.The second transseptal puncture was completed and the patient¿s blood pressure dropped.Ultrasound confirmed a pericardial effusion.The physician believed the event was caused by either the first or second transseptal crossing.No ablation cathter was used; no ablations were performed.No other bwi products were being used.The physician¿s opinion is that the cause of this event was procedure.Device evaluation details: the device evaluation has been completed.The returned device was visually inspected, and it was found in normal conditions.The magnetic, electrical features were tested, and no issues were observed.In addition, the catheter was deflecting and irrigating correctly.No malfunctions were observed during the product analysis.A manufacturing record evaluation was performed for the finished device 30388214l number, and no internal action was found during the review.The catheter passed all specifications.The root cause of the adverse event remains unknown.The (instruction for use) ifu states that careful catheter manipulation must be performed to avoid cardiac damage, perforation or tamponade.If additional information is received regarding this event, a supplemental 3500a report will be submitted to the fda.Manufacturer's ref.# (b)(4).
|